Skip to main content

Aardvark Therapeutics, Inc.

corporate_fare Company Profile

Aardvark Therapeutics, Inc.

AARD·NASDAQ·Life Sciences·CIK 0001774857

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops new small-molecule treatments to activate natural homeostatic pathways for metabolic diseases. The company focuses on biological pathways linked to hunger relief, aiming for significant patient outcomes. Aardvark Therapeutics develops selective compounds that target Bitter Taste Receptors (TAS2Rs) for conditions related to hunger. Its initial compounds target TAS2Rs found in the gut lumen, which typically respond to food chemicals and are part of the gut-brain axis. Research indicates that activating these receptors can trigger the release of natural signaling molecules such as cholecystokinin (CCK), peptide YY (PYY), and glucagon-like peptide-1 (GLP-1). TAS2Rs are a family of 26 nutrient-sensing G protein-coupled receptors (GPCRs) found in vertebrates, present in the mouth for bitter taste and highly expressed in other tissues where they regulate metabolic and inflammatory pathways. CCK is a pharmaceutical target known to suppress hunger. The company's wholly-owned lead product candidate, ARD-101, is an oral, largely gut-restricted small-molecule agonist of specific TAS2Rs in the gut lumen. ARD-101 induces the body's natural release of CCK through TAS2R agonism, differing from prior approaches that directly agonized CCK receptors and faced safety concerns due to systemic exposure and adverse effects like pancreatitis. Aardvark Therapeutics is not aware of any other approved or clinical-stage candidates targeting certain TAS2Rs besides its own.

Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for AARD at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for AARD spans 8-K, 10-Q, PRE 14A, 424B5.

Recent high-impact activity:

  • Aardvark Books Q1 2027 FDA Meeting to Map ARD-101 Restart After Hold Lifted
  • Q3 Loss Widens to 88 Cents a Share, Missing Consensus by 16 Cents
  • Aardvark Q3 Loss Widens to $19.2M; Cash Down to $60.3M With Runway Into 2027
  • Aardvark Posts Exploratory HERO/OLE Data, Targets New Phase 3 After FDA Hold Lift
  • FDA Lifts Clinical Hold on ARD-101, Reviving PWS Program

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$57.59M
Diluted EPS
-$2.93
Op. Cash Flow
-$54.17M
Free Cash Flow
-$54.27M
Operating Income
-$62.73M
Cash & Equivalents
$47.05M
Debt / Equity
0.00×
Shares Outstanding
21.82M sh
Source: 10-K · filed 2026-03-23 · accession 0001193125-26-119770

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 1,038,938 shares in AARD as of the October 30, 2026 settlement, a 87.8% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 20, 2026, 73.0% of AARD volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)1,038,938 shares as of October 30, 2026
Change vs prior period▲ 87.8%
Days to cover1.00 at avg daily volume of 2,760,064
Daily short volume (FINRA facilities)73.0% of 123,760 shares on November 20, 2026
5-day average short volume60.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with A →
$0.9226
52-week range · as of 2026-11-13 $0.9226 – $16.6
Market cap
$20.2M
Volume
241.1K (0.2× avg)
3-mo avg 1.2M
Live data · 2026-11-21 03:37 UTC · Market overnight

show_chartPrice Chart

Loading chart...

feed AARD - Latest Insights

AARD
Nov 13, 2026, 8:18 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $0.9226 info
Change: -$0.5971 (-39%) info
Market Cap: $20.197M info
AARD
Nov 13, 2026, 7:47 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1.52
Real-time Price: $0.9226 info
Change: -$0.5974 (-39%) info
Market Cap: $20.197M info
AARD
Nov 12, 2026, 7:56 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.51
Real-time Price: $0.9226 info
Change: -$0.5874 (-39%) info
Market Cap: $20.197M info
AARD
Oct 23, 2026, 8:38 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.09
Real-time Price: $0.9226 info
Change: -$2.17 (-70%) info
Market Cap: $20.197M info
AARD
Oct 22, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $3.95
Real-time Price: $0.9226 info
Change: -$3.03 (-77%) info
Market Cap: $20.197M info
AARD
Aug 11, 2026, 5:09 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.33
Real-time Price: $0.9226 info
Change: -$6.41 (-87%) info
Market Cap: $20.197M info
AARD
Aug 11, 2026, 5:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.33
Real-time Price: $0.9226 info
Change: -$6.41 (-87%) info
Market Cap: $20.197M info
AARD
Jun 29, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $5.18
Real-time Price: $0.9226 info
Change: -$4.26 (-82%) info
Market Cap: $20.197M info
AARD
Jun 12, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.90
Real-time Price: $0.9226 info
Change: -$2.98 (-76%) info
Market Cap: $20.197M info
AARD
May 21, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $4.37
Real-time Price: $0.9226 info
Change: -$3.45 (-79%) info
Market Cap: $20.197M info
AARD
May 14, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $6.10
Real-time Price: $0.9226 info
Change: -$5.18 (-85%) info
Market Cap: $20.197M info
AARD
May 07, 2026, 9:32 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $5.72
Real-time Price: $0.9226 info
Change: -$4.80 (-84%) info
Market Cap: $20.197M info
AARD
May 07, 2026, 9:28 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.81
Real-time Price: $0.9226 info
Change: -$4.89 (-84%) info
Market Cap: $20.197M info
AARD
May 07, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.81
Real-time Price: $0.9226 info
Change: -$4.89 (-84%) info
Market Cap: $20.197M info
AARD
Apr 03, 2026, 4:05 PM EDT
Filing Type: 424B5
Importance Score:
9
Price at Filing: $4.36
Real-time Price: $0.9226 info
Change: -$3.44 (-79%) info
Market Cap: $20.197M info
AARD
Mar 23, 2026, 6:30 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.00
Real-time Price: $0.9226 info
Change: -$3.08 (-77%) info
Market Cap: $20.197M info
AARD
Mar 23, 2026, 5:10 PM EDT
Filing Type: S-3
Importance Score:
9
Price at Filing: $4.14
Real-time Price: $0.9226 info
Change: -$3.22 (-78%) info
Market Cap: $20.197M info
AARD
Mar 23, 2026, 4:45 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $4.14
Real-time Price: $0.9226 info
Change: -$3.22 (-78%) info
Market Cap: $20.197M info
AARD
Mar 23, 2026, 4:19 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $4.14
Real-time Price: $0.9226 info
Change: -$3.22 (-78%) info
Market Cap: $20.197M info
AARD
Mar 23, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.14
Real-time Price: $0.9226 info
Change: -$3.22 (-78%) info
Market Cap: $20.197M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets